Management of Accelerated Phase Myeloproliferative Neoplasms
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
EP: 1.Myeloproliferative Neoplasms: Essential Thrombocythemia
EP: 2.Managing Patients with Essential Thrombocythemia
EP: 3.Myeloproliferative Neoplasms: Polycythemia Vera
EP: 4.Treatment Options for Polycythemia Vera
EP: 5.PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
EP: 6.Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
EP: 7.Myeloproliferative Neoplasms: Myelofibrosis
EP: 8.Risk Stratification for Myelofibrosis
EP: 9.Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials
EP: 10.New JAK Inhibitors in Myelofibrosis Treatment
EP: 11.Efficacy and Safety of JAK Inhibitors for Myelofibrosis
EP: 12.Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
EP: 13.Novel Agents Under Investigation for Myelofibrosis
Now Viewing
EP: 14.Management of Accelerated Phase Myeloproliferative Neoplasms
EP: 15.Clinical Scenario: A 67-Year-Old with Myelofibrosis
EP: 16.Myelofibrosis Treatment Approaches after Disease Progression
EP: 17.Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
EP: 18.The Future of Myeloproliferative Neoplasm Treatment
Related Videos
Related Content
